Please ensure Javascript is enabled for purposes of website accessibility

2 Best Reddit Healthcare Stocks to Buy Now

By Zhiyuan Sun - Updated Apr 15, 2021 at 2:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These high-risk, high-reward healthcare stocks have outperformed the market over the past year.

Over the past quarter, traders of the legendary r/WallStreetBets have propelled shares of GameStopAMC Entertainment Holdings, and BlackBerry to some mouth-watering (albeit roller-coaster-like) returns. The same group of investors is now eyeing two medical stocks, Trevena (TRVN -5.80%) and Tonix Pharmaceuticals (TNXP 1.90%).

The two firms are identical in that they rely almost entirely on the success of one drug in their respective pipelines. Betting on the future of one product is always risky, but it has its upside as well. Trevena and Tonix stocks are up almost 250% and 55%, respectively, over the past 12 months. Let's look at how they can further enrich investors. 

A woman using a smartphone, with illustrations of financial, health, and other applications surrounding the phone.

Image source: Getty Images.

1. Trevena

Right now, Trevena has no product revenue and a quarterly net loss of $11.9 million per quarter, but a market cap of $283 million. What gives? 

As investors know, a company's valuation isn't only about how much cash flow it generates, but also about future earnings potential based on its assets -- and Trevena is eyeing up a $1.5 billion market opportunity. Last year, the company secured regulatory approval of its drug, Olinvyk, for the treatment of acute pain in hospital and controlled clinical setting. It launched the opioid for use in the first quarter of 2021 for $17.50 per milligram (mg).

The company plans to target 9 million surgical procedures with its medication out of 45 million operations each year in the U.S. Compared to traditional opioids, like intravenous (IV) morphine, Olinvyk offers slightly less analgesia but a much better safety profile. Patients are far less likely to suffer from nausea, vomiting, dizziness, and critical respiratory events after receiving Olinvyk instead of IV morphine. 

Based on its list price and safety benefits, Trevena thinks it can help hospitals achieve 10 times in medical savings by switching from IV morphine to its new branded opioid. In a recent survey (conducted by Trevena), 75% of pharmacists and physicians found Olinvyk's study results meaningful. In other words, they saw clinical and safety benefits in the drug's respiratory and gastrointestinal profiles. While it scales up, the company has more than $100 million in cash and equivalents on its balance sheet and is well funded through the end of 2022. Trevena is a great under-the-radar stock by the merit of this new drug. 

2. Tonix Pharmaceuticals 

Tonix Pharmaceuticals is a $382 million market cap company with a $17 million quarterly net loss and no revenue. Its intangible asset, TNX-102 SL (sublingual cyclobenzaprine), which is being studied for the management of fibromyalgia, is what's backing up the current share price. Tonix is well positioned to capitalize off the $764.1 million market to treat the condition.

Fibromyalgia is a chronic condition that affects 2% to 4% of the U.S. population. It causes recurring pain, sleep disturbances, fatigue, and cognitive symptoms. There is currently no cure for the disease. 

In phase 3 clinical trials, patients who took TNX-102 SL saw their pain symptoms decrease by 1.9 from baseline on the Daily Numeric Pain Rating Scale (NPRS). Patients who received a placebo had a 1.5-point baseline decrease in their pain symptoms. The difference of 0.4 was small, but highly statistically significant. However, an endpoint measuring patients' overall impression of change compared to the placebo cohort was not met, albeit by a slim margin.

Although the results might not seem very all that impressive at first glance, keep in mind that fibromyalgia has always been a challenging condition to treat. Patients with fibromyalgia frequently take two or three medications simultaneously to manage their pain, with 50% discontinuing one course of therapy in 12 months. The last medication approved to treat fibromyalgia, AbbVie's (ABBV 0.42%) Savella, still managed to hit $130 million in peak sales despite only marginally improving patients' condition. 

That's not all: Tonix is also exploring TNX-102 SL for treating post-traumatic stress disorder, agitation in Alzheimer's disease, and alcohol use disorder. Aside from that, the company also has TNX-1300 in phase 2 for treating cocaine intoxication. Tonix also has a variety of preclinical programs in the works targeting COVID-19. I'd highly recommend healthcare investors with a healthy appetite for risk add this one to their watch lists.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Trevena, Inc. Stock Quote
Trevena, Inc.
TRVN
$0.39 (-5.80%) $0.02
BlackBerry Stock Quote
BlackBerry
BB
$5.45 (1.11%) $0.06
GameStop Corp. Stock Quote
GameStop Corp.
GME
$123.42 (0.92%) $1.12
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$153.80 (0.42%) $0.64
AMC Entertainment Holdings, Inc. Stock Quote
AMC Entertainment Holdings, Inc.
AMC
$13.53 (-0.15%) $0.02
Tonix Pharmaceuticals Holding Corp. Stock Quote
Tonix Pharmaceuticals Holding Corp.
TNXP
$1.61 (1.90%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.